Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
Stocktwits on MSN
Why did Ironwood Pharmaceuticals stock skyrocket today?
The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026. ・U.S. FDA had approved ...
FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...
The FDA has approved linaclotide (Linzess) for children aged 7 years or older with irritable bowel syndrome with constipation (IBS-C), making it the first approved treatment for pediatric IBS-C. The ...
The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' (NASDAQ:IRWD) drug Linzess to include the treatment of functional constipation in children and teens. Linzess ...
Please provide your email address to receive an email when new articles are posted on . AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...
The FDA approved an oral suspension product that combines omeprazole and sodium bicarbonate (Konvomep) to treat benign active gastric ulcers and reduce the risk of upper gastrointestinal bleeds in ...
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback